2/29/2024

Isoniazid Tablets

Products Affected - Description

- Isoniazid, Marlex, 300 mg, bottle, 30 count, NDC 10135-0584-30
- Isoniazid, Marlex, 300 mg, bottle, 100 count, NDC 10135-0584-01
- Isoniazid oral tablet, Mylan (Viatris), 300 mg, unit-dose blister pack, 100 count, NDC 51079-0083-20
- Isoniazid oral tablet, Teva, 300 mg, bottle, 30 count, NDC 00555-0071-01

Reason for the Shortage

- Mylan did not provide a reason for the shortage.
- Teva did not provide a reason for the shortage.
- Marlex did not provide a reason for the shortage.

Available Products

- Isoniazid oral tablet, Teva, 100 mg, bottle, 100 count, NDC 00555-0066-02
- Isoniazid oral tablet, Teva, 300 mg, bottle, 100 count, NDC 00555-0071-02

Estimated Resupply Dates

- Marlex has isoniazid 300 mg tablets in 30 count and 100 count bottles on long-term back order and the company cannot estimate a release date.
- Mylan has isoniazid 300 mg tablets in 100 count unit-dose packages on intermittent back order and the company is releasing supplies as they become available.
- Teva has isoniazid 300 mg tablets in 30 count on back order and the company estimates a release date of early-March 2024.

Updated

Updated February 29, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 1, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.